AstraZeneca (AZ) expands phase III COVID-19 vaccine trial of AZD1222 into U.S.

AZ, which is developing vaccine with University of Oxford, has published results from phase I/II trial at 5 UK locations, with 1077 healthy volunteers demonstrating a positive effect. U.S. expansion will recruit up to 30,000 adults who are healthy/with stable medical conditions.


Biospace Inc.